Wan You-Dong, Zhu Rui-Xue, Bian Zhong-Zheng, Sun Tong-Wen
Integrated Intensive Care Unit, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Health Management Centre, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China.
World J Gastroenterol. 2021 Jan 14;27(2):224-232. doi: 10.3748/wjg.v27.i2.224.
Acute pancreatitis is the leading cause of hospitalization for acute gastrointestinal disease worldwide. The effects of probiotics in mild acute pancreatitis have not been studied. We hypothesized that the administration of probiotics may accelerate the recovery of intestinal function and shorten the length of hospital stay (LOS) in patients with mild pancreatitis.
To investigate the value of probiotics in reducing the LOS in patients with mild acute pancreatitis.
We conducted a double-blind randomized clinical trial to evaluate the effects of probiotics administered to patients with mild acute pancreatitis at a tertiary medical center. The patients were given probiotics capsules (a mixed preparation of and ) or placebo. The primary study endpoint was the LOS. The secondary endpoints included time to abdominal pain relief, recurrent abdominal pain, and time to successful oral feeding.
A total of 128 patients were included, with 64 patients in each arm. The severity of illness and the etiological distribution of disease were similar in the two groups. There was a significant reduction in the LOS in the probiotics treatment group the placebo group (5.36 ± 0.15 6.02 ± 0.17 d, < 0.05). The probiotics group was associated with a shorter time to abdominal pain relief and time to successful oral feeding ( < 0.01 for both) than the placebo group. No statistical difference was found in recurrent abdominal pain between the two groups.
The study results showed that the administration of probiotics capsules is associated with a shorter duration of hospitalization in patients with mild acute pancreatitis.
急性胰腺炎是全球急性胃肠疾病住院治疗的主要原因。益生菌在轻度急性胰腺炎中的作用尚未得到研究。我们假设给予益生菌可能会加速轻度胰腺炎患者肠道功能的恢复并缩短住院时间(LOS)。
探讨益生菌在缩短轻度急性胰腺炎患者住院时间方面的价值。
我们在一家三级医疗中心进行了一项双盲随机临床试验,以评估给予轻度急性胰腺炎患者益生菌的效果。患者被给予益生菌胶囊( 和 的混合制剂)或安慰剂。主要研究终点是住院时间。次要终点包括腹痛缓解时间、复发性腹痛以及成功经口进食的时间。
共纳入128例患者,每组64例。两组患者的疾病严重程度和病因分布相似。益生菌治疗组的住院时间较安慰剂组显著缩短(5.36±0.15天对6.02±0.17天,P<0.05)。与安慰剂组相比,益生菌组的腹痛缓解时间和成功经口进食时间更短(两者均P<0.01)。两组复发性腹痛无统计学差异。
研究结果表明,给予益生菌胶囊与轻度急性胰腺炎患者较短的住院时间相关。